SMARCB1 and neoplasm: Moreover, it will be important to examine the generalisability of our findings to other tumours driven by the biallelic loss of SMARCB1 and other members of the BAF chromatin-remodelling complex, in particular AT/RT which are considered to be the intracranial counterpart of MRT.